Covid-19: Antibody cocktail used to treat Trump launched in India at Rs 59,750/dose

The Fact News Service
New Delhi, May 26
Roche India and Cipla, two drug majors have launched anti-body cocktail drugs in India for the treatment of mild to moderate cases of COVID-19. The cocktail drug (Casirivimab and Imdevimab), has been priced at Rs 59, 750 per dose. The product has received emergency use authorization by the Central Drug Standard Control Organisation (CDSO) for treating COVID-19 on May 5. In the joint statement, Roche India and Cipla informed that the first batch of the drug is presently available while the second will be available in India by mid-June.

More from this section